UPCOMING SESSIONS in ET
Tue, Nov 10, 2026
6:00 – 7:00 AM Bangkok
Less Stress, Better Care: Prepare for Tests, Procedures and Results Colin Kloock Register
UPCOMING SESSIONS in ET
Tue, Nov 10, 2026 · 6:00 – 7:00 AM Bangkok
Less Stress, Better Care: Prepare for Tests, Procedures and Results
Colin Kloock
Register
View all sessions

Alnylam Rises as Investors Weigh Pipeline Momentum, Earnings Setup, and ATTR-CM Positioning

Source
Quiverquant

Alnylam Pharmaceuticals (ALNY) is up 3.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a mix of company-specific momentum and sector positioning rather than one single headline. Investors may be reacting to Alnylam’s recent neuroscience update, the scheduled July 30, 2026 second-quarter earnings report, and the company’s strengthened standing in ATTR-CM after a rival late-stage study failed earlier this month.